Skip to main navigation
Ascendis Pharma Logo
  • Overview
  • Events & Presentations
  • News Releases
    • For Global Media Only
    • For U.S. Media Only
  • Corporate Governance
    • Corporate Governance Documents & Charters
    • Leadership
    • Committee Composition
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
  • Financial & Filings
    • Quarterly Reports
    • SEC Filings
    • Annual General Meeting
    • Extraordinary General Meeting
      • Sept. 9, 2022 EGM
      • Nov. 18, 2021 EGM

News Releases
Intended for U.S. Media Only

News Releases

May 7, 2026
Ascendis Pharma Reports First Quarter 2026 Financial Results
May 6, 2026
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
April 30, 2026
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
April 21, 2026
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
April 20, 2026
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
April 8, 2026
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
April 8, 2026
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
April 6, 2026
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
March 17, 2026
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
March 16, 2026
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 17

Shareholder Tools

RSS Feeds
Email Alerts
IR Contact

Footer Corporate Menu

  • TransCon
  • About us
  • Pipeline
  • Patients
  • Investors & News
  • Contact Us

Footer Copyrights Menu

  • Privacy Policy
  • Terms of Use
Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group
© May 2026 Ascendis Pharma